Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYNK-Exo
- Development stage
- Preclinical
- Lead developer
- Celularity
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CYNK-Exo is an exosome-based therapeutic candidate derived from **CYNK-001**, which is **Celularity's** allogeneic, off-the-shelf human placental CD34+ derived natural killer (NK) cell therapy. These exosomes are specifically engineered to deliver short interfering RNA (siRNA) targeting **Transforming Growth Factor-beta (TGF-β)**, a key mediator of immunosuppression in the tumor microenvironment. CYNK-Exo is being developed primarily for the treatment of **Glioblastoma Multiforme (GBM)**, leveraging the natural ability of exosomes to cross the blood-brain barrier. The therapy combines the inherent anti-tumor cytotoxicity of NK cell-derived exosomes with the targeted knockdown of TGF-β to enhance immune responses and potentially synergize with other NK cell therapies like CYNK-001.
- Other names
- CYNK-001-derived exosomesCYNK001-derived exosomesCYNK 001-derived exosomessiCYNK-Exo
02
Targets
TGFB2 (Transforming growth factor beta 2)
Beyond the preview
Go deeper on CYNK-Exo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYNK-Exo.